Drugs / CD19/CD20 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04700319 | Apr 2019 → May 2021 | — | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/CD20 CAR-T | “CD19/CD20 CAR-T cell infusion” NCT04700319 ↗ |
| Modality | Cell therapy | “autologous chimeric antigen receptor T cell infusion targeting CD19/CD20” NCT04700319 ↗ |
| Route | Intravenous | “CD19/CD20 CAR-T,Infusion,iv” NCT04700319 ↗ |